Market Overview:
The global viral vector and plasmid DNA market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth of this market is mainly attributed to the increasing prevalence of cancer, virus infection, and hereditary disease. In addition, the increasing demand for gene therapy and rising investment in R&D are also contributing to the growth of this market. On the basis of type, the global viral vector and plasmid DNA market is segmented into plasmid DNA and viral vector. Plasmid DNA dominates this market owing to its advantages such as easy production process, low cost, high stability under stress conditions, and large-scale production capacity. On the basis of application, this market is segmented into cancer therapy, virus infection therapy (HIV/AIDS), genetic disorders (cystic fibrosis), ophthalmology (retinal diseases), neurology (Parkinson’s disease) & Huntington’s disease), cardiology (heart failure & myocardial infarction) endocrinology (diabetes mellitus). Cancer dominates this application segment owing to rising incidence rates for various types of cancers across different geographies worldwide.
Product Definition:
A viral vector is a virus that has been genetically modified to carry a foreign gene into a host cell. This gene can then be used to produce the desired protein. Plasmid DNA is a circular piece of DNA that exists outside of the chromosomes in bacteria. It is often used as a vector for genetic engineering because it is easy to insert into cells and it replicates independently of the bacterial chromosome. Plasmid DNA can be used to ferry genes into target cells, making it an important tool for genetic engineering.
Plasmid DNA:
Plasmid DNA is a small, circular piece of DNA that carries genes for useful traits. Plasmid DNA can be used as a viral vector to carry out gene transfer in cells. The most common way to do this is by infecting the cell with an extrachromosomal particle (XCP) that contains the plasmid along with some extra genes.
Viral Vector:
Viral vectors are DNA molecules used in viral gene therapy. They are designed to carry a gene for producing a desired protein into the cell. Viral vectors can be distinguished from bacterial artificial chromosomes (BACs) and plasmid DNA by their size and structure. Bacterial artificial chromosome is usually much larger than plasmid DNA, around 1000 genes whereas plasmid DNA generally contains only one or two genes.
Application Insights:
The application segment of the global viral vector and plasmid DNA market is categorized into cancer, virus infection, and hereditary disease. The cancer segment held the largest share in 2017 due to increase in usage of viral vectors for tumor cell delivery. Moreover, introduction of new oncolytic viruses that are less toxic than others is expected to drive growth over the forecast period. For instance, Pox-19-based oncolytic virotherapy has shown encouraging results in preclinical models which can be used for further development leading to reduced toxicity and better efficacy.
On other hand, use of plasmid DNA as a carrier for hepatitis C treatment is gaining significant popularity owing to its low cost and easy accessibility which may result in high demand over next few years. Plasmid based hepatitis C treatments have lower rates of adverse effects when compared with current therapies thus making them more suitable for clinical trials purposes as well as commercialization efforts afterwards.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a substantial number of biotechnology and pharmaceutical companies involved in viral vector development. Moreover, increasing R&D activities by several major players is also one of the key factors contributing to regional growth. The U.S., being a developed economy, has fewer restrictions on commercialization than developing nations such as India or China which have witnessed exponential growth in recent years due to increased focus on science & technology among common mass populace.
Asia Pacific is expected to grow at an exponential rate during the forecast period due to rising awareness about emerging diseases and their treatment options along with government support for promoting biosimilars that are based on virus-based therapy over conventional ones like drug delivery systems or stem cell transplantation therapies that require expensive equipment & skilled professionals for implementation leading towards high cost associated with these therapies thus hampering its accessibility even within countries themselves thereby hindering overall regional growth prospects considerably.
Growth Factors:
- Increasing demand for gene therapy and regenerative medicine
- Rising prevalence of chronic diseases
- Growing number of research institutes and universities
- Technological advancements in viral vector and plasmid DNA delivery systems
- Increasing public-private investments in R&D
Scope Of The Report
Report Attributes
Report Details
Report Title
Viral Vector and Plasmid DNA Market Research Report
By Type
Plasmid DNA, Viral Vector
By Application
Cancer, Virus Infection, Hereditary Disease
By Companies
Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector, Lonza, BioReliance, MolMed, FUJIFILM Diosynth Biotechnologies, UniQure, Aldevron, Richter-Helm, Eurogentec, OBiO Technology, Yposkesi, Cell and Gene Therapy Catapult, MassBiologics, Biovian, VGXI, Gene Synthesis, PlasmidFactory, Jikai Gene
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Viral Vector and Plasmid DNA Market Report Segments:
The global Viral Vector and Plasmid DNA market is segmented on the basis of:
Types
Plasmid DNA, Viral Vector
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Cancer, Virus Infection, Hereditary Disease
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Brammer Bio
- Oxford BioMedica
- Cobra Biologics
- FinVector
- Lonza
- BioReliance
- MolMed
- FUJIFILM Diosynth Biotechnologies
- UniQure
- Aldevron
- Richter-Helm
- Eurogentec
- OBiO Technology
- Yposkesi
- Cell and Gene Therapy Catapult
- MassBiologics
- Biovian
- VGXI
- Gene Synthesis
- PlasmidFactory
- Jikai Gene
Highlights of The Viral Vector and Plasmid DNA Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Plasmid DNA
- Viral Vector
- By Application:
- Cancer
- Virus Infection
- Hereditary Disease
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Viral Vector and Plasmid DNA Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Viral vector and plasmid DNA are two types of vectors. Viral vectors are viruses that can carry genes from one cell to another. Plasmid DNA is a type of vector that uses pieces of genetic material, called plasmids, which can be easily inserted into other cells.
Some of the major players in the viral vector and plasmid dna market are Brammer Bio, Oxford BioMedica, Cobra Biologics, FinVector, Lonza, BioReliance, MolMed, FUJIFILM Diosynth Biotechnologies, UniQure, Aldevron, Richter-Helm, Eurogentec, OBiO Technology, Yposkesi, Cell and Gene Therapy Catapult, MassBiologics, Biovian, VGXI, Gene Synthesis, PlasmidFactory, Jikai Gene.
The viral vector and plasmid dna market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Viral Vector and Plasmid DNA Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Viral Vector and Plasmid DNA Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Viral Vector and Plasmid DNA Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Viral Vector and Plasmid DNA Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Viral Vector and Plasmid DNA Market Size & Forecast, 2020-2028
4.5.1 Viral Vector and Plasmid DNA Market Size and Y-o-Y Growth
4.5.2 Viral Vector and Plasmid DNA Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Plasmid DNA
5.2.2 Viral Vector
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Cancer
6.2.2 Virus Infection
6.2.3 Hereditary Disease
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Viral Vector and Plasmid DNA Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Viral Vector and Plasmid DNA Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Plasmid DNA
9.6.2 Viral Vector
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Cancer
9.10.2 Virus Infection
9.10.3 Hereditary Disease
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Plasmid DNA
10.6.2 Viral Vector
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Cancer
10.10.2 Virus Infection
10.10.3 Hereditary Disease
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Plasmid DNA
11.6.2 Viral Vector
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Cancer
11.10.2 Virus Infection
11.10.3 Hereditary Disease
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Plasmid DNA
12.6.2 Viral Vector
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Cancer
12.10.2 Virus Infection
12.10.3 Hereditary Disease
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Plasmid DNA
13.6.2 Viral Vector
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Cancer
13.10.2 Virus Infection
13.10.3 Hereditary Disease
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Viral Vector and Plasmid DNA Market: Competitive Dashboard
14.2 Global Viral Vector and Plasmid DNA Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Brammer Bio
14.3.2 Oxford BioMedica
14.3.3 Cobra Biologics
14.3.4 FinVector
14.3.5 Lonza
14.3.6 BioReliance
14.3.7 MolMed
14.3.8 FUJIFILM Diosynth Biotechnologies
14.3.9 UniQure
14.3.10 Aldevron
14.3.11 Richter-Helm
14.3.12 Eurogentec
14.3.13 OBiO Technology
14.3.14 Yposkesi
14.3.15 Cell and Gene Therapy Catapult
14.3.16 MassBiologics
14.3.17 Biovian
14.3.18 VGXI
14.3.19 Gene Synthesis
14.3.20 PlasmidFactory
14.3.21 Jikai Gene
